Stay updated on Trastuzumab Emtansine in HER2+ Tumors Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page.

Latest updates to the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision label updated to v3.5.0 with the v3.4.3 label removed.SummaryDifference0.0%

- Check15 days agoChange DetectedRevision labels updated: v3.4.3 added and v3.4.2 removed.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check44 days agoChange DetectedRevision: v3.4.2 was added to the site, and the previous funding-status notice (v3.4.1) was removed.SummaryDifference0.4%

- Check51 days agoChange DetectedNew site-wide notice about lapse in government funding and NIH Clinical Center operations is now visible, and the page revision has been updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check58 days agoChange DetectedAdded a glossary toggle and updated page metadata labels (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act data') with a revision bump from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check72 days agoChange DetectedAdded a site revision note: 'Revision: v3.3.4' and removed 'Revision: v3.3.3'; no study data, eligibility criteria, outcomes, or locations were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Trastuzumab Emtansine in HER2+ Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Emtansine in HER2+ Tumors Clinical Trial page.